TABLE 3.

Healthcare resource utilization during the 12‐month follow‐up period

	All‐cause outpatient visits (n = 1730)		All‐cause hospitalizations (n = 125)		Phototherapy	Topical treatment
	Frequency, [95% CI], (PPPM)	Duration between visits, Mean (SD), days	Frequency, [95% CI], (PPPM)	Duration, Mean (SD), days a	Frequency, [95% CI], (PPPM)	n (%)
Total	2.0 [2.0, 2.0]	14.5 (18.8)	0.01 [0.01, 0.01]	12.8 (18.8)	0.18 [0.17, 0.19]	1617 (93.5)
TNF inhibitor	1.7 [1.6, 1.9]	17.0 (19.0)	0.00 [0.00, 0.02]	3 (0.0)	0.00 [0.00, 0.02]	22 (88)
IL‐12/23 inhibitor	1.4 [1.2, 1.5]	21.7 (25.4)	0.01 [0.00, 0.03]	58.3 (49.5)	0.00 [0.00, 0.00]	21 (87.5)
IL‐17 inhibitor	2.3 [2.2, 2.4]	12.3 (17.5)	0.01 [0.00,0.01]	6.0 (6.2)	0.00 [0.00,0.01]	44 (73.3)
IL‐23 inhibitor	1.7 [1.6, 1.9]	17.0 (18.3)	0.00 [0.00, 0.02]	2 (0.0)	0.00 [0.00, 0.00]	20 (71.4)
PDE‐4 inhibitor	2.1 [2.0, 2.1]	14.0 (17.6)	0.01 [0.00, 0.01]	9.2 (19.0)	0.25 [0.24, 0.26]	917 (96.2)
Immunosuppressant	1.8 [1.8, 1.8]	15.7 (21.1)	0.01 [0.01, 0.02]	14.1 (15.1)	0.04 [0.04, 0.05]	336 (89.1)
Vitamin A	2.0 [2.0, 2.1]	14.2 (19.8)	0.01 [0.01, 0.02]	15.4 (16.1)	0.22 [0.21, 0.24]	257 (97.7)

Note: TNF inhibitor includes adalimumab. IL‐12/23 inhibitor includes ustekinumab. IL‐23 inhibitor includes guselkumab. IL‐17 inhibitors include secukinumab and brodalumab. PDE‐4 inhibitor includes apremilast. Immunosuppressant includes cyclosporin. Vitamin A includes etretinate.

Abbreviations: CI, confidence interval; IL, interleukin; n, number of patients; PDE‐4, phosphodiesterase‐4; PPPM, per person per month; SD, standard deviation; TNF, tumor necrosis factor.

^a For patients having at least one hospitalization.